Companies › Newish Technology (Beijing)
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NWRD06 Glypican 3 (GPC3)-targeted DNA plasmid vaccine | GPC3 | Phase 2 | Hepatocellular Carcinoma (HCC) | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07324304 | NWRD06 | Phase 2 | Hepatocellular Carcinoma (HCC) | Oncology | Dec 2028 |
BrainChild Bio TVAX Biomedical Lukas Biomedical RhoVac APS March Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.